Clinical applications of new antithrombotic agents

Annals of Hematology

Volumn 72, Issue 4, 1996, Pages 177-183

  Beijering, R J R ^a   Ten Cate, H ^b   Ten Cate, J W ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Slotervaartziekenhuis ^*  (Netherlands)

Author keywords

Antithrombotic agents; Hirudin; Low molecular weigth heparin; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10A; DANAPAROID; HEPARIN; HEPARIN BINDING PROTEIN; HEPARINOID; HIRUDIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PROTHROMBIN; STREPTOKINASE; THROMBIN; THROMBIN INHIBITOR;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; CORONARY ARTERY DILATATION; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; FIBRINOLYTIC THERAPY; HEART ATRIUM THROMBOSIS; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; MAJOR SURGERY; OSTEOPENIA; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; THROMBOEMBOLISM;

EID: 0029918642     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050158     Document Type: Review

References (52)

1. Agnelli G. Cosmi B. Di Filippo P et al. (1992) A randomized, double blind, placebo controlled trial of dermatan sulphate for prevention of deep-vein thrombosis in hip fracture. Thromb Haemost 67:203-208
2. Andcrsson L-O, Barrowcliffe TW, Johnson EA et al (1976) Anticoagulant properties of heparin fractioned by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 9:575-583
3. Andersson LO. Barrowcliffe TW, Holmer E et al. (1979) Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma. Thromb Res 15:531-541
4. Antman EM, for the TIMI 9A Investigators (1994) Hirudin in acute myocardial infarction. Circulation 90:1624-1630
5. Bach RR (1988) Initiation of coagulation by tissue factor. Crit Rev Biochem 23:339-367
6. Barrowcliffe TW. Merton RE. Havercroft SJ et al. (1984) Low-affinity heparin potentiates the action of high-affinity heparin oligosaccharide. Thromb Res 34:125-133
7. Bendayan P, Boccalon H, Dupouy D, Boneu B (1994) Dermatan sulfate is a more potent inhibitor of clot-bound throm-bin than unfractionated and low-molecular-weight heparins. Thromb Haemost 71:576-580
8. Bittl FA, Strony J. Brinker JA et al. (1995) Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Enal J Med 333:764-769
9. Bode C. Hudelmayer M. Mehwald P et al. (1994) Fibrin-targeted recombinant hirudin inhibits fibrin deposition on experimental clots more efficiently than recombinant hirudin. Circulation 90:1956-1963
10. Buchwald AB, Unterberg C, Nebendahl K et al. 1992 Lowmolecular-weight heparin reduces neointimal proliferation after coronary stent implantation in hypercholesterolemic minipigs. Circulation 86:531-537
11. Cannon CP, McCabe CH, Henry TD et al. (1994) A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 5 trial. J Am Coll Cardiol 23:993-1003
12. Fox I, Dawson A, Loynds P et al. (1993) Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost 69:157-163
13. Ginsberg JS, Nurmohamed MT, Gent M et al. (1994) Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 90:2385-2389
14. The global use of strategies to open occluded coronary arteries (GUSTO) IIa investigators (1994) Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 90:1631-1637
15. Harker LA, Maraganore JM, Hirsh J (1994) Novel antithrombotic agents. In: Colman RW, Hirsh J, Marder VM, Salzman EV (eds) Hemostasis and Thrombosis: basic principles and clinical practice, 3rd edn. Lippincott, pp 1638-1660
16. Harker LA, Hanson SR, Kelly AB (1995) Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonist. Thromb Haemost 74:464-472
17. Herbert JM, Herault JP. Barzu T, Bernat A. Lormeau JC, Petitou M (1995) Biochemical and pharmacological properties of sanorg 32701. a potent analogue of the natural pentasaccharide. Thromb Haemost 73:1321. mr. 1617
18. Hirsh J, Levine MN (1992) Low-molecular-weight heparin. Blood 79:1-17
19. Hook M, Bjork I. Hopwood J et al. (1976) Anticoagulant activity of heparin: separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin. FEBS Letters 66:90-93
20. Jorgensen LN, Wille-Jorgensen P, Hauch O (1993) Prophylaxis of postoperative thromboembolism with low-molecular-weiaht heparins. Br J Surg 80:689-704
21. Kay R. Sing Wong K, Yuk Ling Yu, Yuk Wah Chan et al. (1995), Low-molecular-weight heparin for the treatment of acute ischmic stroke, N Engl J Med 333. (No. 24) 1588-1593
22. Koopman MMW, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administrated in the hospital as compared with subcutaneous low-molecular weight heparin administered at home. (1996) New England. J Mediane 334:682-687
23. Lam LH, Silbert JE, Rosenberg RD (1976) The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 69:570-577
24. Lane DA. Denton J. Flynn AM et al. (1984) Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 218:725-732
25. Lane DA, Ryan K. Ireland H, Curtis JR, Nurmohamed MT, Krediet RT, Roggekamp MC Stevens P. ten Cate JW (1992) Dermatan sulphate in haemodialysis. Lancet 339:334-335
26. Leizorovicz A, Haugh MC, Chapuis F-R et al. (1992) Low-molecular-weight heparin in prevention of perioperative thrombosis. Br Med J 305:913-920
27. Leizorovicz A, Simonneau G, Decousus H. Boissel JP (1994) Comparison of efficacy and safety of low-molecular-weight heparins and unfractionated heparin in initial treatment of deep-vein thrombosis: a meta-analysis. Br Med J 309:299-304
28. Lensing AWA, Prins MH, Davidson BL, Hirsh J (1995) Treatment of deep venous thrombosis with low-molccular-weight heparins. Arch Intern Med. 155:601-607
29. Lidon R-M, Theroux P, Lesperance J et al. (1994) A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 89:1567-1572
30. Magnani HN (1993). Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 70:554-561
31. Maraganore JM, Bourdon P, Jablonski J et al. (1990) Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin. Biochemistry 29:7095-7101
32. Marbet GA, Verstraete M, Kienast J et al. (1993) Clinical pharmacology of intravenously administered recombinant desulfalohirudin (CGP 39393) in healthy volunteers. J Cardiovasc Pharmacol 22:364-372
33. Markwardt F (1994) The development of hirudin as an antithrombotic drug. Thromb Res 74.1-23
34. Meyer BL, Fernandez-Ortiz A, Mailhac A et al. (1994) Local delivery of r-hirudin by a double balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty. Circulation 90:2474-2480
35. Neuhaus KL, von Essen R, Tebbe U et al. (1994) Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study. Circulation 90:1638-1642
36. Nurmohamed MT, ten Cate J, Stevens P et al. (1991) Long-term efficacy and safety of a low-molecular-weight heparin in chronic hemodialysis patients. A comparison with standard heparin. ASAIO Trans 37: M 459-461
37. Nurmohamed MT, Rosendaal FR, Buller HR et al. (1992) Low -molecular-weight heparin in general and orthopedic surgery: a meta analysis. Lancet 340:152-156
38. Nurmohamed MT, Buller HR, ten Cate JW (1994) Low-molecular-weight heparins in extracorporeal circuits. In: Bounameaux H (ed) Low-molecular-weight heparins in prophylaxis and therapy of thromboembolic diseases. Marcel Dekker, New York, pp 247-271
39. Parent F, Bridey F, Dreyfus M et al. (1993) Treatment of severe venous thrombo-embolism with intravenous hirudin (HBW 023): an open pilot study. Thromb Haemost 70:386-388
40. Pawashe A, Ezekowitz M, Lin TC et al. (1991), Molecular cloning, characterization and expression of cDNA for rabbit brain tissue factor. Thromb Haemost 66:315-320
41. Pejler G (1988) Why does heparin bind antithrombm? Thesis. Swedish University of Agricultural Science, Uppsala
42. Rasmussen C. Wadt J. Jacobsen B (1994) Thromboembolic prophylaxis with low-molecular-weight heparin during pregnancy, Int J Gynaecol Obstet 47:121-125
43. Serruys PW, Herrman JR, Simon R et al. (1995) A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 333:757-763
44. ten Cate H, Henny CP, ten Cate JW et al. (1987) Randomized double-blind, placebo controlled safety study of a low-molecular-weight heparinoid in patients undergoing transurethral resection of the prostate. Thromb Haemost 57:92-96
45. ten Cate H, Henny CP, ten Cate JW, Buller HR (1988) Clinical studies with low-molecular-weight heparin (oid)s: an interim analysis. Am J Hematol 27:146-153
46. Thomas DP, Merton RE, Barrowcliffe TW et al. (1982) Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis. Thromb Haemost 47:244-248
47. Topol EJ (1995), Novel antithrombotic approaches to coronary artery disease. Am J Cardiol 75:27B-33B
48. Topol EJ, Fuster V. Harrington RA et al. (1994) Recombinant hirudin for unstable angina pectoris. Circulation 89:1557-1566
49. van den Bos AA, Deckers JW, Heyndrickx GR et al. (1993) Safety and efficacy of recombinant hirudin (CGP 39393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation 88:2058-2066
50. Vogel GMT, van Amsterdam RGM, Kop WJ Meuleman DG (1993) Pentasaccharide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt. Thromb Haemost 69:29-34
51. Walenga JM. Petitou M, Lormeau JC et al. (1987) Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb Res 46:187-198
52. Weitz JI. Hudoba M. Massel D et al. (1992), Clot-bound thrombin is protected from inhibition by heparin-antithrombin III, but is susceptible to mactivation by antithrombin III independent inhibitor. J Clin Invest 86:385-391